Can we pull the plug on warfarin in atrial fibrillation?

This publication has 7 references indexed in Scilit:

• Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial
  The Lancet, 2003
• Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation: SPORTIF ii: a dose-guiding, tolerability, and safety study
  Journal of the American College of Cardiology, 2003
• Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial
  The Lancet, 2002
• Oral Anticoagulation for Acute Coronary Syndromes
  Circulation, 2002
• Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison
  The Lancet, 2000
• Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial
  The Lancet, 1996
• Optimal Oral Anticoagulant Therapy in Patients with Mechanical Heart Valves
  New England Journal of Medicine, 1995